Case Study: Precision Medicine Group achieves 50% faster patient enrollment, 75% site reduction and $20M cost savings with Medable eConsent

How Medable eConsent expands patient access, reduces costs and improves time to treatment

Precision Medicine Group, focused on developing new therapies for age-related macular degeneration, faced an infeasible study design that required 100+ sites and was constrained by patient proximity and budget, delaying the trial for years. They selected Medable’s eConsent (part of the Medable DCT Platform) to digitize screening and consent and broaden patient access.

Medable deployed a five-step decentralized workflow using eConsent, eRecruitment, and Direct-to-Patient Shipments to enable 100% remote screening and flexible visit scheduling. The solution cut sites from 100 to 25, reduced total trial costs by $20M, and halved enrollment time from two years to one year, enabling Precision Medicine Group to launch the study for the first time.

Precision Medicine Group